Courses of treatment.
| EGPA Patients with IVIG, n = 22 | EGPA Patients without IVIG, n = 24 | p | |
|---|---|---|---|
| PSL as initial dose, mg/kg | 0.96 ± 0.2 | 0.8 ± 0.2 | NS† |
| Patients given steroid pulse (%) | 68.2 | 54.2 | NS* |
| Patients taking immunosuppressant (%) | 95.5 | 79.2 | NS* |
| CYC/AZA/CSA | 21/0/0 | 16/1/2 | NS* |
| Median time from onset to initial IVIG treatment, mo (range) | 3.5 (1.0–216.0) | ||
| IVIG, no. courses, mean ± SD | 2.6 ± 2.1 | 0 | p < 0.01† |
| Mean time from first IVIG to last treatment, mo | 9.2 ± 10.0 | ||
| PSL at 2 yrs after last IVIG or about 38 mo from onset, mg | 5.5 ± 2.4 | 7.7 ± 2.9 | p < 0.01† |
Values of p < 0.05 considered statistically significant.
↵† 2-way ANOVA with repeated measures among 2 groups.
↵* Chi-square testing revealed no significant differences in the frequencies of 2 groups. EGPA: eosinophilic granulomatosis with polyangiitis; NS: not significant; PSL: prednisolone; CYC: cyclophosphamide; AZA: azathioprine; CSA: cyclosporine; IVIG: intravenous immunoglobulin.